Antibiofilm agent-23

Antibiofilm agent-23 (compound 5) (1.25-20 μM; 24 h) inhibits P. aeruginosa PAO1 biofilm formation in a dose-dependent manner, with inhibition rates of 51.2% and 58.3% at 10 and 20 μM, respectively^[1].
Antibiofilm agent-23 (1.25-20 μM; 2 h) disperses mature P. aeruginosa PAO1 biofilms, significantly increasing planktonic bacterial counts at concentrations ≥ 1.25 μM^[1].
Antibiofilm agent-23 (1.25-20 μM; 24 h) reduces the production of P. aeruginosa virulence factors, including elastase (44.6% reduction at 20 μM), rhamnolipid (19.7% reduction at 20 μM), and pyocyanin (66.7% reduction at 20 μM)^[1].
Antibiofilm agent-23 selectively inhibits the pqs QS pathway in P. aeruginosa PAO1-pqsA-gfp reporter strain in a dose-dependent manner, while showing weak or no inhibition of the las and rhl pathways^[1].
Antibiofilm agent-23 (20 μM) significantly elicits siderophore production, increasing pyoverdine (PVD) by 11.1-fold and pyochelin (PCH) by 1.5-fold in P. aeruginosa PAO1^[1].
Antibiofilm agent-23 (20 μM) in combination with sub-MIC Ciprofloxacin (HY-B0356) shows synergistic antibacterial activity against P. aeruginosa PAO1 and MDR clinical isolates (1121, 1129, 1167, and FB)^[1].
Antibiofilm agent-23 (up to 100 μM; 48 h) shows low cytotoxicity in HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.